home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


David Hirsh



Emma Naks

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
Confocal Microscopy

Diabetes Focus

Olympus’s Helge Schmidt questions Professor Simone Baltrusch at the University of Rostock about her investigation into the role of the mitochondrial network in diabetes and how confocal microscopy is advancing academic research in the field.
Legal, Regulatory and Public Policy
America Invents Act

Patents Overhauled

Tom Scourfield and Andrew Payne at CMS review the America Invents Act, noting that, although its requirements have gone some way towards harmonising regulation with the rest of the world, some provisions remain unique to the US.
In Brief

The Weakest Link

Emile Bellott reflects on current approaches to precision medicine, and suggests how the industry can make the most of research funding.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October
Banner of Eppendorf on Samedan
Banner of Samedan app.EBR on Samedan
Industry Events

Analytical Method Development, Validation and Transfer

15-16 September 2015, Maritim proArte Hotel Berlin, Germany

Informa Life Sciences' 5th Annual Analytical Method Development, Validation and Transfer is a dedicated forum focusing on industry case studies, regulatory agency feedback and interactive formats to enable increased speed and efficiency.
More info >>

News and Press Releases

Molekule Consulting Inc Today Announces its Exhibiting at the 2015 Pharma Competitive Intelligence Conference and Exhibition USA

At the Pharma CI USA Conference, Mr. Alderman will present a talk entitled, “CI=ROI. Emerging Markets in biopharmaceuticals – how leveraging primary competitive intelligence returns robust ROIs in key global growth driver markets” where he will discuss emerging markets as targets and subjects of competitive intelligence research.
More info >>

air transport logo


White Papers

Phase II trial of Trigemina’s TI-001 for high frequency migraine

Exco InTouch Ltd

Trigemina’s TI-001 is a patented application of a formulation including oxytocin with a novel mode of action (MOA) as a therapy for high frequency migraine. Open label data suggests that TI-001 holds the promise to be safe and effective in reducing moderate and severe headache day frequency among this population by more than 50%, with corresponding decreases in secondary migraine symptoms (nausea, vomiting etc.) and use of acute medications, a significant improvement compared to current drugs.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement